



# SERODUS

---

## SERODUS ASA

**Interim report  
First quarter 2020  
and subsequent events  
(Unaudited)**

May 2020

## Q1-2020 Highlights

- Private placement postponed 1,5 months until May 2020 due to the global financial situation
- Nine months toxicological testing of SER150 in one species finalized
- Planning the next clinical study continue
- One new use SER150 patent has been filed

### SER150 for Diabetic Kidney Disease

Draft reports of all toxicological studies have been approved by Serodus and are about to be finally signed a little earlier than first anticipated

The clinical study will be a 3 months SER150 dosing study in 100 patients. The patients will have type 2 diabetes and have macro-albuminuria at inclusion in the study, that means more than 300 mg albumin/g creatinine.

Serodus plan to perform the study in Australia and in Denmark and expect to file the application to the responsible authorities in the respective countries in Q2 2020.

The background for performing the next clinical study in Australia is the governments strong financial support to research and development including clinical drug development and that the quality of clinical research is recognized internationally to have a very high standard.

Up to now the Covid-19 pandemic has only modestly affected Serodus.

### SER130 for Diabetic Retinopathy

Nothing to report

### SER140

Nothing new to report

## Financials

Financial statement for the first quarter 2020 compared to same quarter 2019.

Serodus is able to finance development activities into 2020-Q2 but in order to initiate the next clinical study additional funding is needed.

In February 2020 Serodus made an agreement with Translution Capital ApS regarding a mandate to find an investor(s) to fund the planned confirmatory study in Australia. Teaser and presentation material were produced through March 2020.

In early March Serodus Launched a Private Placement with an offering of 4.770.300 as authorized by the AGM 2019 to the board of directors. This was open to existing as well as new investors. Due to the turmoil caused by Covid-19, the Board decided in late March to extend the subscription period until mid-May 2020.

At the end of 2020-Q1 Serodus had app. NOK 4,7 million in cash.

## Profit & Loss

(All figures in thousand NOK)	Q1 '2020	Q1 '2019	YTD 2020	YTD 2019
<i>Operating income</i>				
Revenue	-	-	-	-
<i>Operating expenses</i>				
Cost of sales	-	-	-	-
Project cost	(704)	(8.442)	(704)	(8.442)
Personnel expenses	(793)	(1.697)	(793)	(1.697)
Depreciation and Amortization of assets	(11)	(45)	(11)	(45)
Other Operating Expenses	(908)	(942)	(908)	(942)
<b>Total Operating Expenses</b>	<b>(2.415)</b>	<b>(11.126)</b>	<b>(2.415)</b>	<b>(11.126)</b>
<b>Operating result</b>	<b>(2.415)</b>	<b>(11.126)</b>	<b>(2.415)</b>	<b>(11.126)</b>
<b>Net finance</b>	<b>(41)</b>	<b>(124)</b>	<b>(41)</b>	<b>(124)</b>
<b>Profit/ (loss) before tax</b>	<b>(2.457)</b>	<b>(11.250)</b>	<b>(2.457)</b>	<b>(11.250)</b>
Tax	-	-	-	-
<b>Profit/ (loss) after tax</b>	<b>(2.457)</b>	<b>(11.250)</b>	<b>(2.457)</b>	<b>(11.250)</b>

## Balance Sheet

(All figures in thousand NOK)	31-03-2020	31-03-2019
<b>ASSETS</b>		
<i>Assets</i>		
Intangible assets	628	2.219
Goodwill	-	599
<b>Sum intangible assets</b>	<b>628</b>	<b>2.818</b>
<i>Current assets</i>		
Inventories	6.700	4.874
Other short term receivables	1.357	
Bank	4.655	28.873
<b>Sum Current assets</b>	<b>12.712</b>	<b>33.747</b>
<b>Sum assets</b>	<b>13.340</b>	<b>36.565</b>
<b>EQUITY AND DEBT</b>		
Share capital	10.455	133.797
Share premium reserve	-	50.948
Other equity	34.480	(4.461)
Capital not registered		
Retained earnings	(32.828)	(150.560)
<b>Sum equity</b>	<b>12.108</b>	<b>29.724</b>
<i>Long term debt</i>		
Convertible loan	-	-
Deferred tax	(11)	392
<b>Sum long term debt</b>	<b>(11)</b>	<b>392</b>
<i>Short term debt</i>		
Accounts payable	730	5.503
Other short term debt	513	947
<b>Sum short term debt</b>	<b>1.243</b>	<b>6.450</b>
<b>Sum equity and debt</b>	<b>13.340</b>	<b>36.565</b>

## Cash flow

(All figures in thousand NOK)	Q1 '2020	Q1 '2019	YTD 2020	YTD 2019
<b>Cash flow from operating activities</b>				
Ordinary profit/(loss) before tax	(2.457)	(11.250)	(2.457)	(11.250)
Amortization of assets				
Depreciation of assets	11	45	11	45
Placement expenses booked booked directly to equity				
Share based payments				
Changes in accounts receivables, creditors and inventory	(4.246)	(4.665)	(4.246)	(4.665)
Changes in accruals	(773)	235	(773)	235
<b>Net cash flow from operating activities</b>	<b>(7.464)</b>	<b>(15.635)</b>	<b>(7.464)</b>	<b>(15.635)</b>
<b>Cash flow from investing activities</b>				
Investment in assets	-	-	-	-
<b>net cash flow from investing activities</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Cash flow from financing activities</b>				
Proceeds from issue of share capital Capital not registered	-	27.378	-	27.378
Convertible loan	-	-	-	-
Emmision acquisition of shares Phlogo				
Issue expences recognized directly in equity				
Repayment of loans				
<b>Net cash flow from financing activities</b>	<b>-</b>	<b>27.378</b>	<b>-</b>	<b>27.378</b>
<b>Net changes in cash and cash equivalents</b>	<b>(7.464)</b>	<b>11.743</b>	<b>(7.464)</b>	<b>11.743</b>
Cash and cash equivalents at the beginning of the period	12.119	17.130	12.119	17.130
<b>Cash and cash equivalents at the end of the period</b>	<b>4.655</b>	<b>28.873</b>	<b>4.655</b>	<b>28.873</b>

## Equity

### YTD 2020

(All figures in thousand NOK)	Share capital	Share premium reserve	Other paid inn equity	Retained earnings	Total equity
Equity 01.01.2020	10.455	-	34.480	(30.357)	14.579
- Profit/(loss) for the period				(2.457)	(2.457)
- Other revenue/expenses				-	-
<i>Total comprehensive income</i>	-	-	-	(2.457)	(2.457)
<i>Transaction costs</i>					-
Sharebased payments					-
Conversion of debt					-
Capital not registered					-
Issue of shares					-
Foreign exchange change Equity				(15)	(15)
Capital reduction					-
<b>Equity 31.03.2020</b>	<b>10.455</b>	<b>-</b>	<b>34.480</b>	<b>(32.828)</b>	<b>12.108</b>

\* In Q2 2019 a reverse sharesplit was made 10:1

## Key Figures

(All figures in thousand NOK)	Q1 '2020	Q1 '2019	YTD 2020	YTD 2019
Total operating revenue	-	-	-	-
Net operating expenses	(2.415)	(11.126)	(2.415)	(11.126)
<b>Operating profit (loss)</b>	<b>(2.415)</b>	<b>(11.126)</b>	<b>(2.415)</b>	<b>(11.126)</b>
<b>Total comprehensive income(loss) for the period</b>	<b>(2.457)</b>	<b>(11.250)</b>	<b>(2.457)</b>	<b>(11.250)</b>
Diluted earnings (loss) per share	(0,23)	(0,11)	(0,23)	(0,11)
Number of employees	3	3	3	3
Cash and equivalents at end of period	4.655	28.873	4.655	28.873

Board of Directors and CEO

May 2020

Serodus ASA